Hexarelin vs GHRP-6: Key Differences

Hexarelin and GHRP-6 are the two most studied hexapeptides in the GHRP (growth hormone releasing peptide) family, and the core difference between them is not what they do — both activate the ghrelin receptor, GHS-R1a, to stimulate growth hormone release — but how strongly each one activates it and what side effects come with that activation. GHRP-6 shows the strongest appetite-stimulating effect of the two in the models studied. Hexarelin is more potent at releasing GH and is the only one of the two with its own line of cardiac tissue research.

What they have in common

Both are synthetic hexapeptides in the same pharmacological class: growth hormone secretagogues acting on the same receptor as endogenous ghrelin. Neither is a GHRH analog — that's a separate family that includes CJC-1295 no DAC and Sermorelin, which act on a different receptor, GHRH-R. GHRP-6 and Hexarelin also share the same pulsatile release mechanism: the stimulus produces a transient spike, not a sustained elevation, and that kinetic profile is one of the points most commonly compared between the two in experimental pharmacology literature.

Where they differ structurally

Both are hexapeptides, but they don't share the same amino acid sequence. GHRP-6 was the prototype developed in the 1980s from Bowers's original work on GH-releasing peptides. Hexarelin is a later molecule, specifically designed to increase potency and receptor affinity relative to first-generation GHRPs, GHRP-6 among them. That sequence difference is what explains, in published in vitro and in vivo models, why Hexarelin requires a lower concentration to produce the same degree of receptor activation.

Receptor affinity and potency

The literature describes Hexarelin as the GHRP with the highest binding affinity for GHS-R1a of the entire group, higher than GHRP-6 and GHRP-2. In comparative GH-release assays, Hexarelin produces equivalent responses at lower experimental doses than GHRP-6. This doesn't make it "better" — it makes each one the right tool for a different research question, depending on whether the experimental design needs to maximize signal at lower molar exposure or replicate the profile of a reference GHRP with decades of published studies behind it.

Appetite: the difference most cited in the literature

Of the two, GHRP-6 is the one most consistently associated with increased appetite in the animal models studied, an effect it shares with endogenous ghrelin and that is explained by its action on hypothalamic receptors linked to hunger regulation. Hexarelin, although it acts on the same receptor, shows a more moderate orexigenic (appetite-stimulating) effect in comparative studies. This is the difference cited most often when one GHRP is compared against another, and it's also the reason an experimental design aiming to isolate the GH axis without the appetite variable tends to prefer Hexarelin as the reference molecule.

Cortisol and prolactin

Both peptides, by activating the ghrelin receptor, also stimulate cortisol and prolactin release to varying degrees — a side effect of the mechanism, not the target of research in most designs. GHRP-6 tends to show a more pronounced effect on these two hormones in published studies. That's relevant for any experimental protocol using either one as a stimulus: if cortisol or prolactin are variables of interest in the same assay, it's worth documenting before designing the experiment, because the cross-hormonal noise can confound the reading of the GH axis.

Hexarelin and the heart: a separate research line

What most sharply distinguishes Hexarelin from GHRP-6, and from nearly the rest of the GHRP family, is that it has its own line of cardiac tissue research that doesn't depend on GH release. Several in vitro and in vivo studies describe effects of Hexarelin on cardiomyocytes and ischemia models that persist even when the growth hormone axis is blocked, suggesting a secondary mechanism of action, likely mediated by a distinct ghrelin receptor subtype present in cardiac tissue. GHRP-6 does not have an equivalent published research line at that volume. This is why, in the literature, Hexarelin appears more often in cardiovascular research contexts, while GHRP-6 is more associated with metabolic and feeding-behavior research.

What studies report on stability

Both are relatively short, stable hexapeptides as lyophilized powder, with the usual sensitivity of any peptide to humidity and temperature cycling once reconstituted in solution. Relative stability between the two is not the axis of comparison that dominates the literature — unlike potency, appetite, or the cardiovascular line — so any experimental design that depends on shelf life in solution should rely on the certificate of analysis for the specific batch, not on a generalization across peptides.

Research use only, not for human consumption

Hexarelin and GHRP-6, like every other peptide PeptoClinic quotes, are supplied exclusively for laboratory research (Research Use Only). They are not approved for human or veterinary use, they are not medicines or supplements, and no claim about them has been evaluated by the FDA, ANMAT, or an equivalent authority. PeptoClinic is not a pharmacy, a clinic, or a telehealth provider, does not issue or require a prescription, and does not offer dosing, administration, or protocol guidance — any inquiry oriented toward human use is declined.

Documentation and traceability when quoting

When the research question requires directly comparing Hexarelin and GHRP-6 — same design, same reference batch, same cold chain — the documentation that ships with each order is what makes the experiment reproducible. PeptoClinic works to a purity standard of ≥99% HPLC on the research peptides in its catalog and documents each batch before it ships. You can see how to read a certificate of analysis and what to ask before accepting a batch on the quality page. For shipments to Argentina, the logistics and the import file prepared as laboratory reference material are described on the Argentina page.